Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Estrella Immunopharma ( (ESLA) ) has issued an announcement.
On November 3, 2025, Estrella Immunopharma announced the successful completion of the second dose cohort in the Phase I portion of its STARLIGHT-1 Phase I/II clinical trial of EB103, a CD19-redirected ARTEMIS® T-cell therapy for Advanced B-Cell Non-Hodgkin’s Lymphomas. The trial achieved a 100% complete response rate at Month 1 among all evaluable patients, who were considered high-risk and unsuitable for commercial CD19 products. No treatment-related serious adverse events were reported, highlighting EB103’s potential as a safe and effective treatment for a broader patient population. Following this milestone, a Data and Safety Monitoring Board will review the data to determine the Recommended Phase II Dose for the trial’s expansion phase.
The most recent analyst rating on (ESLA) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Estrella Immunopharma stock, see the ESLA Stock Forecast page.
More about Estrella Immunopharma
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies for the treatment of cancer and autoimmune diseases. The company’s mission is to leverage the human immune system to transform the lives of patients battling these conditions. Estrella’s lead product candidate, EB103, targets CD19, a protein found on most B-cell leukemias and lymphomas, using ARTEMIS® technology licensed from Eureka Therapeutics, Inc.
Average Trading Volume: 195,724
Technical Sentiment Signal: Buy
Current Market Cap: $84.88M
For a thorough assessment of ESLA stock, go to TipRanks’ Stock Analysis page.